{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=90", "query": { "condition": "Ovarian Tumors", "page": 90 }, "page_size": 10 }, "pagination": { "page": 90, "page_size": 10, "total_count": 2465, "total_pages": 247, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=91&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=89&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T01:25:42.663Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05585034", "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Melanoma Excluding Uveal Melanoma", "Non-small Cell Lung Cancer, Squamous or Non-squamous", "Urothelial Carcinoma", "Renal Cell Carcinoma, Clear Cell", "Castration-resistant Prostate Cancer", "Ovarian Cancer, Epithelial", "TNBC - Triple-Negative Breast Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "XmAb®808", "type": "BIOLOGICAL" }, { "name": "Keytruda® (pembrolizumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2022-12-14", "completion_date": "2025-05-20", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-11-02T01:25:42.663Z", "location_count": 12, "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585034" }, { "nct_id": "NCT00096239", "title": "CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "CP-547,632", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2004-12", "completion_date": "2005-02", "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-11-02T01:25:42.663Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096239" }, { "nct_id": "NCT02020707", "title": "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosarcoma", "Cervical Adenosquamous Carcinoma", "Cervical Carcinosarcoma", "Cervical Squamous Cell Carcinoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Carcinosarcoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Squamous Cell Carcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Malignant Female Reproductive System Neoplasm", "Malignant Ovarian Clear Cell Tumor", "Malignant Ovarian Endometrioid Tumor", "Malignant Ovarian Epithelial Tumor", "Malignant Ovarian Mucinous Tumor", "Malignant Peritoneal Neoplasm", "Malignant Solid Neoplasm", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal Clear Cell Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Unresectable Melanoma", "Uterine Corpus Carcinosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2014-02-24", "completion_date": "2024-07-18", "has_results": false, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-11-02T01:25:42.663Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02020707" }, { "nct_id": "NCT00004230", "title": "Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "captopril", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "1999-10", "completion_date": "2002-03", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-11-02T01:25:42.663Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004230" }, { "nct_id": "NCT00137865", "title": "Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "EGEN-001 (phIL-12-005/PPC)", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "EGEN, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2005-08", "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-11-02T01:25:42.663Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00137865" }, { "nct_id": "NCT03842865", "title": "Expanded Access of Vigil in Solid Tumors", "overall_status": "TEMPORARILY_NOT_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Solid Tumor", "Ewing Sarcoma", "Ewing's Tumor Metastatic", "Ewing's Sarcoma Metastatic", "Advanced Gynecological Cancers", "Ovarian Cancer", "Cervical Cancer", "Uterine Cancer" ], "interventions": [ { "name": "Vigil", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gradalis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-06-05", "last_synced_at": "2026-11-02T01:25:42.663Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03842865" }, { "nct_id": "NCT02855944", "title": "ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "pharmaand GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 349, "start_date": "2017-03-01", "completion_date": "2022-09-16", "has_results": true, "last_update_posted_date": "2023-06-09", "last_synced_at": "2026-11-02T01:25:42.663Z", "location_count": 2, "location_summary": "Denver, Colorado • Augusta, Georgia", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02855944" }, { "nct_id": "NCT03323398", "title": "Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Solid Tumor Malignancies or Lymphoma", "Ovarian Cancer" ], "interventions": [ { "name": "mRNA-2416", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2017-08-15", "completion_date": "2021-08-18", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-11-02T01:25:42.663Z", "location_count": 9, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 5 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03323398" }, { "nct_id": "NCT04729387", "title": "Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 358, "start_date": "2021-07-22", "completion_date": "2026-01-19", "has_results": true, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-02T01:25:42.663Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Fort Myers, Florida • West Palm Beach, Florida + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729387" }, { "nct_id": "NCT00275028", "title": "AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Primary Peritoneal Serous Adenocarcinoma", "Recurrent Ovarian Epithelial Cancer", "Stage I Ovarian Epithelial Cancer", "Stage II Ovarian Epithelial Cancer" ], "interventions": [ { "name": "cediranib maleate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 47, "start_date": "2005-10", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2015-11-09", "last_synced_at": "2026-11-02T01:25:42.663Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00275028" } ] }